Oral Drug Delivery Videos

  1. Effective Supplier Management In Drug Delivery Development With Suttons Creek 9/25/2025

    In this episode of In Combination, Albana Thorpe and Max Lerman from the technical director team at drug delivery product development consultancy Suttons Creek discuss with host Tom von Gunden, chief editor at Drug Delivery Leader, considerations around supplier relationships in product development for combination products and other delivery devices. Albana and Max share perspectives on quality management, documentation, usability testing, regulatory pathways, post-market design changes, and other aspects of supplier controls. 

  2. Advances In Oral GLP-1 Analogs For Obesity 9/12/2024

    Discover how these groundbreaking Oral GLP-1 Analogs therapies are reshaping obesity management and addressing key challenges in formulation and delivery.

  3. Oral Drug Delivery For Breast Cancer Prevention With Atossa Therapeutics' Steven Quay 4/7/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Atossa Therapeutics CEO Steven Quay about oral drug delivery for early intervention in patients at high risk of breast cancer. The discussion covers formulations, coatings, and dosing for orally administered, cancer-preventative approaches to reducing breast density. 

  4. When And How To Use A UFMEA During Device Design 12/11/2024

    When and how might using a uFMEA (Use Failure Mode Effects Analysis) tool benefit biopharma companies addressing regulatory expectations for analyses of risk and/or human factors? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, and Shannon Hoste, chief scientific officer at Pathway for Patient Health, discuss potential differences in the contexts, purposes, and degrees of detail in information presented for review.

  5. Breakthroughs In Bioavailability For Orally Delivered Drugs 6/12/2026

    In this segment of the Drug Delivery Leader Live online event, Advanced Oral Delivery: Maximizing Molecules, Targets, And Adherence, Chief Editor Tom von Gunden asks panelist Firouz Asgarzadeh to highlight key breakthroughs in oral drug delivery effectiveness. Asgarzadeh underscores advances in bioavailability. Panelists Jing Ling and Eduardo Jule weigh in on solubility and the foundational function of the Target Product Profile (TPP). 

  6. The Landscape For Advanced Therapies And Combination Products 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, traces key conditions driving and impacting the development of advanced therapies and combination products. These include the demand for precision medicines, the complexity of regulatory frameworks, and pressures on healthcare systems. 

  7. Rapid Development Of Amorphous Solid Dispersions For Bioavailability

    See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

  8. Solvent-Free, Fusion-Based Amorphic Dispersion Process 7/11/2024

    Discover a solvent-free, fusion-based process that leverages frictional and shear forces to rapidly convert crystalline drugs and polymers into amorphous solid dispersions (ASDs).

  9. Transforming Drug Delivery. Transforming Lives. 8/29/2024

    Watch this introduction to Adare Pharma Solutions, a global technology driven CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry. 

  10. Bolstering Bowel And Bladder Control With Dignify Therapeutics' Karl Thor 2/6/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Chief Scientific Officer Karl Thor of Dignify Therapeutics about providing relief for patients suffering from neurogenic bowel and bladder dysfunction.